Skip to main content

Day: December 4, 2023

Priority Income Fund Announces an 11.6% Annualized Cash Distribution Rate (on Class R Offering Price) Through “Bonus” and “Base” Common Shareholder Distributions for December 2023 through February 2024

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) — Priority Income Fund, Inc. (“Priority Income Fund” or the “Fund”) announced today that the Fund’s Board of Directors has declared a steady monthly cash “base” and a quarterly “bonus” common shareholder distribution for December. The Fund also announced a change from quarterly “bonus” distributions to monthly cash “bonus” common shareholder distributions beginning in January 2024. The annualized total cash distribution is $1.38516 per share (11.6% annualized rate for Class R and 12.4% annualized rate for Class I), for distributions with record dates between December 5, 2023 and February 5, 2024 based on the current Class R offering price of $11.96 per common share and the current Class I offering price of $11.15 per common share. The cash “base” distribution will...

Continue reading

Insider information – Clarification of expectations for 2023

COMPANY ANNOUNCEMENT         Odense, December 4th, 2023 Company Announcement no. 45 – 12.04.2023 Insider information – Clarification of expectations for 2023 Danish Aerospace Company A/S (DAC) has previously, for its 2023 Financial Year, announced an expected revenue in the range of DKK 24-26 million and a positive operating profit (EBITDA) in the range of DKK 3-4 million. In connection with the 2023 Interim report, DAC briefed the market on expectations in the lower end compared to both revenue and operating profit (EBITDA). Delays in signing a couple of larger future European Space Agency contracts and contract additions, among them GAINTEX, lead to DAC now expecting a revenue for the Fiscal year 2023 to be in the range of DKK 23 million, just below the lower end of the formerly announced expectation. Further, it is expected that...

Continue reading

Bureau Veritas acquires Impactiva group S.A., expanding its supply chain services offer to the footwear and apparel industry

PRESS RELEASE Neuilly-sur-Seine, France – December 4, 2023 Bureau Veritas acquires Impactiva group S.A., expanding its supply chain services offer to the footwear and apparel industry Bureau Veritas, a global leader in the testing, inspection, and certification (TIC) industry, announces the acquisition of Impactiva Group S.A., a leader in quality assurance for the footwear and apparel industry. Since its establishment in 2003, Impactiva has become a strategic partner for its broad portfolio of top-tier footwear, apparel and leather goods retailers and brand owners. The Company provides guidance to hundreds of factories and tanneries across Asia, Europe and Africa, ensuring the highest levels of quality in production. Known for its innovative solutions, Impactiva optimizes the use of raw materials, minimizes waste, and eliminates finished...

Continue reading

Progressive Announces Dividend Information and 2024 Annual Meeting Record Date

MAYFIELD VILLAGE, OHIO, Dec. 04, 2023 (GLOBE NEWSWIRE) — On December 1, 2023, the Board of Directors of The Progressive Corporation (NYSE:PGR) declared an annual common share dividend, in the amount of $0.75 per share, and a quarterly common share dividend, in the amount of $0.10 per share. Both the annual and quarterly dividends are payable January 26, 2024, to shareholders of record at the close of business on January 19, 2024 (ex-dividend date of January 18, 2024). The annual dividend amount for 2023 was determined by the Board based on our capital position, existing capital resources, and expected current and future capital needs. The Board is expected to continue to declare quarterly dividends for 2024. The Board also set the close of business on March 15, 2024, as the record date for the determination of shareholders entitled...

Continue reading

Correction: Form 8.3 – MOLTEN VENTURES PLC

8.3 AMENDMENT OF SECTIONS 2b & 3aPUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree MOLTEN VENTURES PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date position held/dealing undertaken:        For...

Continue reading

HighCo: Shareholding as 11/30/2023

INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES Declaration pursuant to Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des marchés financiers (AMF)Date of settlementof information Total number of shares Number of shares without voting rights (*) Number of voting rights for threshold calculation (**) Number of actual voting rights (exercisable at shareholders’ meeting)November 30, 2023 20 455 403 696 534 22 382 926 21 686 392October 31, 2023 20 455 403 665 183 22 383 817 21 718 634September 30, 2023 20 455 403 644 867 22 786 847 22 141 980August 31, 2023 20 455 403 534 241 22 786 178 22 251 937July 31, 2023 20 455 403 530 556 22 792 535 22 261 979June 30, 2023 20 455 403 529 405 22 793 847 22 264 442May 31, 2023 20 455 403 485 342 22 793...

Continue reading

Capstone Technologies Appoints Accomplished Sports Executive, Entrepreneur, and Former Professional Athlete Maurice Evans to Board of Directors

CHARLOTTE, N.C., Dec. 04, 2023 (GLOBE NEWSWIRE) — Capstone Technologies Group Inc (OTC: CATG) a leading acquirer, operator and organic developer of disruptive technologies, today announced the appointment of Maurice Evans to its Board of Directors, an accomplished sports executive, entrepreneur, and former professional athlete. Evans is an 11-year NBA veteran who played for multiple NBA franchises such as the Lakers, Pistons, Hawks, Magic, and Wizard to name a few. Evans is the co-founder of The Molo Agency, a purpose-driven talent agency that provides elite representation to professional athletes. Evans also serves as the President of the NBRPA Houston Chapter, comprised of all former NBA, WNBA, ABA, and Harlem Globetrotters who reside in the Houston area.  Evans served as VP of the NBA Players Association from 2009-2013. He was...

Continue reading

Form 8.3 – Molten Ventures PLC

8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree MOLTEN VENTURES PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date position held/dealing undertaken:        For an opening position...

Continue reading

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

BRISBANE, CALIFORNIA, Dec. 04, 2023 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, today announced the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for the development of GTB-3650, a 2nd generation nanobody TriKE® for the treatment of patients with CD33+ leukemia, including relapsed/refractory acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). “Today’s announcement is an important milestone for GT Biopharma, and we look forward to advancing GTB-3650 for treatment of CD33+ leukemia. We are excited to expeditiously move this molecule into the clinic as we execute...

Continue reading

CareCloud Welcomes Justin Pierce as Chief Sales Officer

SOMERSET, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) — CareCloud, Inc. (Nasdaq: CCLD, CCLDP, CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, today announced the appointment of Justin Pierce as its new chief sales officer (CSO). In this role, Pierce will be responsible for driving sustainable revenue growth and enhancing CareCloud’s position in the rapidly evolving healthcare landscape. Pierce brings more than two decades of experience in the healthcare technology and services industry, having held leadership positions at Azalea Health, abeo, and Ventra Health. Throughout his career, he has consistently demonstrated his ability to forge strong relationships with physician group leaders, hospital executives, and healthcare business professionals, helping them address their...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.